Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Fisher & Paykel Healthcare (ASX:FPH) share price drops on product recall

The Fisher & Paykel Healthcare Ltd (ASX: FPH) share price has fallen after announcing a product recall.

Fisher & Paykel describes itself as a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. Its products are sold in over 120 countries.

Fisher & Paykel Healthcare product recall

The company has initiated a “voluntary limited recall” of batches of Airvo 2 and myAirvo 2 devices manufactured before 14 August 2017.

This recall relates to a speaker configuration issue that may result in “distorted, intermittent or inaudible alarm sound levels”. Fisher & Paykel Healthcare said this does not affect the therapy delivered by the devices and they will otherwise perform as intended.

The company said that since 14 August 2017, a new speaker configuration from a different supplier was implemented into the manufacturing of Airvo 2 and myAirvo devices.

For readers that don’t know, those devices are used to deliver “high flow therapy” to patients, though they are not intended for life support. Appropriate patient monitoring is required at all times. If there is an interruption to therapy a patient may experience oxygen desaturation.

How does this affect the Fisher & Paykel Healthcare share price?

Investors clearly think it’s a negative, with the share price down around 1%.

Fisher & Paykel Healthcare said it’s consulting with various international regulatory authorities to initiate appropriate action in each country. It will also contact distributors, dealers and hospitals that may have products subject to this recall and replace any affected devices.

The ASX healthcare share has estimated there are approximately 9,000 of the affected devices remaining in use. Customers can contact their local Fisher & Paykel Healthcare representative, regional sales office or distributor.

The company has estimated the company has estimated the costs will be approximately $12 million, which will be provisioned in the result for the 12 months to 31 March 2024.

Depreciation change

The company also advised that a taxation bill passed its third reading in New Zealand Parliament today, which removes depreciation deductions for commercial and industrial buildings that were reinstated by the previous government “and will likely impact the company’s tax expense” for FY24.

The ASX share said it’s currently unable to quantify the financial impact of these changes.

Final thoughts on the Fisher & Paykel Healthcare share price

A $12 million hit is painful for shareholders, but hopefully it’s just a one-off occurence.

The company is doing the right thing, and hopefully this builds further trust with long-term customers. It also mentioned it has been using a different system for a number of years.

The Fisher & Paykel Healthcare share price has rallied in the last few months, so I wouldn’t call it a cheap buy. I don’t know the business or sector, but I’m cautious around this sort of business because of the unknown (to me) potential of a competitor introducing a better/cheaper product. There are other ASX growth shares I’d rather buy.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content